Neurocrine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.

CEO

Kyle W. Gano

CEOKyle W. Gano

Employees

2,000

Employees2,000

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1992

Founded1992

Employees

2,000

Employees2,000

NBIX Key Statistics

Market cap

16.48B

Market cap16.48B

Price-Earnings ratio

23.81

Price-Earnings ratio23.81

Dividend yield

—

Dividend yield—

Average volume

1.13M

Average volume1.13M

High today

$164.50

High today$164.50

Low today

$155.12

Low today$155.12

Open price

$155.43

Open price$155.43

Volume

629.76K

Volume629.76K

52 Week high

$164.50

52 Week high$164.50

52 Week low

$122.14

52 Week low$122.14

Stock Snapshot

As of today, Neurocrine(NBIX) shares are valued at $163.93. The company's market cap stands at 16.48B, with a P/E ratio of 23.81.

During the trading session on 2026-06-03, Neurocrine(NBIX) shares reached a daily high of $164.50 and a low of $155.12. At a current price of $163.93, the stock is +5.7% higher than the low and still -0.3% under the high.

Trading activity shows a volume of 629.76K, compared to an average daily volume of 1.13M.

The stock's 52-week range extends from a low of $122.14 to a high of $164.50.

NBIX News

Investing.com 4h

Neurocrine to present two-year Crenessity data at ENDO 2026 - Investing.com

...

TipRanks 1d

Neurocrine reinstated with a Buy at Goldman Sachs

Goldman Sachs reinstated coverage of Neurocrine (NBIX) with a Buy rating and $213 price target The completion of the Soleno Therapeutics acquisition bolsters th...

TipRanks 6d

Neurocrine Shareholders Reelect Directors and Approve Governance Measures

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Analyst ratings

88%

of 32 ratings

Buy

87.5%

Hold

12.5%

Sell

More NBIX News

Simply Wall St 6d

A Look At Neurocrine Biosciences Valuation After New INGREZZA Data And Analyst Coverage

Neurocrine Biosciences (NBIX) is back in focus after new real world survey data on INGREZZA in mild tardive dyskinesia, along with fresh analyst coverage, incre...

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.

iShares MSCI Emerging Mar…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.